Atlanta Consulting Group Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-5,876
Closed -$700K 190
2024
Q3
$700K Buy
5,876
+4,037
+220% +$538K 0.17% 102
2024
Q2
$262K Sell
1,839
-2,123
-54% -$281K 0.06% 98
2024
Q1
$509K Buy
+3,962
New +$472K 0.18% 71

Other funds holding NVO

Atlanta Consulting Group Advisors's NVO Position: Q4 2024 in Review

Atlanta Consulting Group Advisors sold out of Novo Nordisk (NVO) in Q4 2024, closing a stake of 5,876 shares — an estimated $700K sold.

Atlanta Consulting Group Advisors first reported a position in NVO in Q1 2024 and held it in 3 quarters. The position peaked at $700K in Q3 2024. 1,663 funds tracked by Wall St. Rank hold NVO as of Q4 2024.

  • Atlanta Consulting Group Advisors reported no remaining Novo Nordisk position as of Q4 2024 after selling out during the quarter.
  • Atlanta Consulting Group Advisors sold 5,876 Novo Nordisk shares in Q4 2024, an estimated $700K.
  • Atlanta Consulting Group Advisors first reported a position in Novo Nordisk in Q1 2024 and held it in 3 quarters.
  • Atlanta Consulting Group Advisors's Novo Nordisk position peaked at $700K in Q3 2024.
  • 1,663 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2024.

Based on Atlanta Consulting Group Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.